ESC Professional Premium Access

Medical management and risk factors

Event: ESC Congress 2022
Topic: Treatment
Session type: Moderated ePosters
Date: 26 August 2022
Time: 08:15 - 09:00

Congress Session

5 presentations in this session

Risk of stroke in patients with type 2 diabetes receiving semaglutide or a dipeptidyl peptidase-4 inhibitor: a real-world US claims database analysis

Speaker: Professor M. Evans (Cardiff, GB)
Thumbnail

Predictive value of neutrophil-to-lymphocyte ratio for atrial fibrillation and stroke in type 2 diabetes mellitus: a population-based cohort study

Speaker: Mr T. Lee (Hong Kong, HK)
Thumbnail

Celiprolol to prevent arterial events in patients with vascular Ehlers-Danlos and neither symptomatic nor silent arterial event. A retrospective cohort study from the French national reference center

Speaker: Professor T. Mirault (Paris, FR)
Thumbnail

Inequalities in accessing quality healthcare, does insurance play a role? retrospective analysis of aortic emergencies from national inpatient sample 2019.

Speaker: Doctor S. Vohra (New Brunswick, US)
Thumbnail

Four-month treatment with long-acting glucagon-like peptide-1 receptor agonists (GLP-1) or sodium-glucose co-trasporter-2 inhibitors (SGLT-2i) improves vascular function in type 2 diabetes mellitus

Speaker: Doctor I. Ikonomidis (Athens, GR)
Thumbnail

5 speakers from this session

Professor Marc Evans

, Cardiff (United Kingdom of Great Britain & Northern Ireland)
1 follower

Mr Teddy Lee

Cardiovascular Analytics Group, Hong Kong (Hong Kong)
0 follower

Professor Tristan Mirault

University Paris City PARCC INSERM U970 European Hospital Georges Pompidou APHP, Paris (France)
0 follower

Doctor Shekhar Vohra

Saint Peter's University Hospital, New Brunswick (United States of America)
0 follower

Doctor Ignatios Ikonomidis

National & Kapodistrian University of Athens, Athens (Greece)
5 presentations
3 followers

This platform is supported by

logo Novo Nordisk